The role of AGE/RAGE in liver disease
Grant number: 1029990 | Funding period: 2012 - 2014
Cirrhosis of the liver due to non-alcoholic fatty liver disease, chronic hepatitis and other liver diseases is now a major cause of illness and death in Australia. This project will examine how advanced glycation end products (AGEs), compounds formed in the body and also derived from our diet, contributes to the progression of liver scarring in these diseases. We will study whether drugs targeting these compounds can be used to reduce liver scarring and prevent the development of cirrhosis.
Related publications (6)
Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
Dinali H Fernando, Josephine M Forbes, Peter W Angus, Chandana B Herath
Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-rela..
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
Eveline Bruinstroop, Rinkoo Dalan, Yang Cao, Yong Mong Bee, Kurumbian Chandran, Li Wei Cho, Shui Boon Soh, Eng Kiong Teo, Sue-Anne Toh, Melvin Khee Shing Leow, Rohit A Sinha, Suresh Anand Sadananthan, Navin Michael, Heather M Stapleton, Christopher Leung, Peter W Angus, Sheila K Patel, Louise M Burrell, Su Chi Lim, Chee Fang Sum
CONTEXT: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associa..
Damage to enteric neurons occurs in mice that develop fatty liver disease but not diabetes in response to a high-fat diet
LR Rivera, C Leung, RV Pustovit, BL Hunne, S Andrikopoulos, C Herath, A Testro, PW Angus, JB Furness
BACKGROUND: Disorders of gastrointestinal functions that are controlled by enteric neurons commonly accompany fatty liver disease...